The Biosimilars Forum announced on 1 February 2016 the launch of a new biosimilars education initiative. The ‘Partnership for Biosimilars Education and Access’ will focus on raising awareness and encouraging access to biosimilars in the US.
Launch of partnership for biosimilars education and access
Biosimilars/General
|
Posted 12/02/2016
0
Post your comment

The forum, which came into being in May 2015 [1], was developed by 11 brand-name and generics companies all involved in developing biosimilars as ‘the first nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States’.
As part of the initiative, the forum has released two educational guides designed to educate healthcare professionals, the media and patient advocacy organizations about biosimilars. The education tools provide detailed background, insights, FAQs and resources on biosimilars that can be used by multiple stakeholders.
The ‘Overview’ educational guide provides background into what biologicals are and continues by providing information on the core principles of biosimilars, which includes sections on what is a biosimilar, as well as biosimilarity, extrapolation and interchangeability. The document also includes a chapter on the US biosimilars pathway and the benefits of biosimilars for society.
The ‘FAQs’ educational guide provides information about biologicals and biosimilars in a question and answer format. Questions in the document include: What are the benefits of biosimilars; Do biosimilars work in the same way as their biological reference products; and How are biosimilars prescribed? among others.
The information is free and available at biosimilarsforum.org
Related article
Concerns raised over CMS biosimilars reimbursement policy
Reference
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars Forum launched [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Feb 12]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-Forum-launched
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.
Source: Biosimilars Forum
Research
Biosimilars in low- and middle-income countries
Positive safety and efficacy primary endpoint results for AVT05 (golimumab proposed biosimilar)
The ustekinumab shift: biosimilars displace Stelara’s market leadership

Biosimilars/General Posted 12/03/2025
Brazilian law establishes December 16 as National Biosimilar Day

Biosimilars/General Posted 05/03/2025
Biosimilar medicines on the Pharmaceutical Benefits Scheme in Australia

Biosimilars/General Posted 20/11/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment